Tizanidine Hydrochloride Capsule
Product Images NDC 70771-1069

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tizanidine Hydrochloride (NDC 70771-1069). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Lifesciences Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (E5aa06ec 9ceb 4c1c 9334 90bef0d9366f 01)

Chemical structure diagram of tizanidine hydrochloride, showing the arrangement of rings and functional groups including a chlorine atom and nitrogen-sulfur heterocyclic components.*

FDA Label Image

Figure (E5aa06ec 9ceb 4c1c 9334 90bef0d9366f 02)

Line graph showing plasma tizanidine concentration (ng/mL) over 24 hours after dosing with 2 x 4 mg tizanidine tablets or capsules, comparing conditions with and without food. The graph includes four series representing tablets and capsules taken with food and without food, illustrating concentration changes over time.*

FDA Label Image

Figure (E5aa06ec 9ceb 4c1c 9334 90bef0d9366f 03)

A line graph showing improvement in Ashworth Score over hours post-dose, comparing 16 mg tizanidine, 8 mg tizanidine, and placebo groups. The y-axis measures improvement, and the x-axis represents time from 0 to 6 hours post-dose. Error bars indicate variability at each time point.*

FDA Label Image

Figure (E5aa06ec 9ceb 4c1c 9334 90bef0d9366f 04)

A line graph showing improvement in Ashworth Score over time, comparing tizanidine (mean dose 28.8 mg) and placebo groups at three points: End of Titration (Study Week 3), End of Maintenance (Study Week 7), and Endpoint (Last Observation Carried Forward). The tizanidine group shows consistent improvement while the placebo group remains near baseline.*

FDA Label Image

Label (E5aa06ec 9ceb 4c1c 9334 90bef0d9366f 05)

Label for Tizanidine Capsules 2 mg by Zydus Lifesciences Limited. The label indicates the oral capsule dosage form with a package size of 150 capsules. It includes a warning that these capsules are not interchangeable with tizanidine tablets or Zanaflex tablets, and storage instructions recommending 20° to 25°C. Manufacturer location is Matoda, Ahmedabad, India.*

FDA Label Image

Label (E5aa06ec 9ceb 4c1c 9334 90bef0d9366f 06)

Tizanidine Capsules 4 mg oral capsules label displaying the active ingredient strength as 4 mg, with a package size of 150 capsules. The label includes a warning that these capsules are not interchangeable with tizanidine tablets or Zanaflex tablets. It is manufactured by Zydus Lifesciences Limited, India, and marked Rx only. Storage and handling instructions are also noted.*

FDA Label Image

Label (E5aa06ec 9ceb 4c1c 9334 90bef0d9366f 07)

Label for Tizanidine Capsules 6 mg by Zydus Lifesciences Limited. The label displays the product name, strength (6 mg), dosage form (capsules), quantity (150 capsules), and prescription status (Rx only). It includes a barcode, NDC 70771-1069-8, storage instructions, child-resistant packaging warning, and a note that the capsules are not interchangeable with certain other tizanidine products.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.